TST002 Intervenous Injection in Postmenopausal Women and Men With Reduced Bone Mineral Density

ClinicalTrials.gov ID

NCT05391776

Lead Sponsor

HJB (Hangzhou) Co., Ltd.INDUSTRY

Overall Status

Unknown status

Study Type

Interventional

Phase

Phase 1

Enrollment

32Estimated

Last Update Posted

May 26, 2022Actual

Start Date

Apr 28, 2022Actual

Primary Completion Date

Apr 28, 2023Estimated

Completion Date

Jun 28, 2023Estimated

Official Title

A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TST002 Intervenous Injection in Postmenopausal Women and Men With Reduced Bone Mineral Density

Brief Summary

This is a placebo-controlled, single-ascending dose, multicenter Phase I clinical study to evaluate the safety, tolerability, PK and PD characteristics of a single intravenous infusion of TST002 in subjects with reduced bone mineral density.

Detailed Description

Four single dose cohorts are designed in this study, ascending with phase I dose-escalation principles as following: 200mg, 400mg (100%), 800mg (100%), and 1200mg (50%). 8 subjects will be enrolled in each cohort, 6 for TST002 injection and 2 for placebo. Only ≤3 male subjects could be enrolled in each cohort. Subjects in each dose group were randomized to receive TST002 or placebo in a ratio of 3:1.

• Osteoporosis

• TST002 Injection
• placebo

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

Subjects must meet all of the following inclusion and exclusion criteria to be enrolled in this study:

1. Voluntarily signe the informed consent, could walk freely, understood the study and is willing to follow it, and could complete all test procedures as planned;
2. Body mass index (BMI) : 18.0-30.0 kg/m2 (inclusive), weight ≥45 kg, BMI= weight (kg)/height 2 (m2);
3. 45-70 years old (inclusive) postmenopausal women who have been in post-menopause for 2 years or more. Menopause is defined as: 1) no spontaneous vaginal bleeding or bleeding for more than 12 months; 2) More than 1 year after bilateral oophorectomy (time for unilateral oophorectomy is calculated according to natural menopause); 3) Hysterectomy: more than 50 years old, serum FSH level & GT; 40 iu/L. 50-75 years old (inclusive) men. Male subjects should agree to use effective, investigator-approved contraceptive methods from the time they sign the informed consent until 3 months after administration.
4. BMD T score at lumbar vertebra L1-L4, total hip or femoral neck < -1.0;
5. Subjects had at least two consecutive vertebrae in L1-L4 and at least one hip bone available for dual-energy DXA bone mineral density assessment;
6. Prior to enrollment, the investigator assessed the subjects to have no medical conditions that would significantly affect the study or may increase additional health risks by asking for medical history, physical examination, and supplementary examination. If the subjects have abnormal examination reports, they can only be enrolled if the investigator evaluates that they do not pose a safety risk to the subjects or do not interfere with the safety evaluation of the clinical study, and explains the reasons.

Exclusion Criteria:

1. Blood donation or bleeding of 400mL or more within 3 months before screening; History of blood transfusion within 3 months prior to screening;

2. People who have a history of drug allergy or allergic constitution;

3. Received systemic glucocorticoid treatment 3 months before screening, and took prednisone equivalent of more than 5mg per day for a total of more than 10 days; Inhalation or topical administration within 2 weeks prior to screening is not included;

4. Have a history of alcohol or drug abuse or tobacco abuse in the past year (smoking more than 5 cigarettes per day).

   Note: Criteria for alcohol intake: weekly alcohol intake &lt; 14 units/week, 1 unit =360 mL beer; Or 150 mL wine; Or 45 mL white wine;

5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is greater than 1.25 times the upper limit of normal value or total bilirubin is greater than 1.1 times the upper limit of normal value; Renal function laboratory examination is judged to be clinically significant by researchers.

6. History of breast cancer (female subjects only); Hereditary family history of breast cancer or known BRCA1/2 gene mutation; Mammography within 6 months prior to screening does not exclude breast cancer.

7. Have a history of thrombocytopenia, or have a platelet count below the lower limit of the normal range during screening;

8. It is clinically significant to have previous diseases or hemorrhagic diseases leading to coagulation abnormalities or coagulation abnormalities during screening period;

9. Those who had a serious injury or major surgical operation within 1 month prior to the screening period, or who planned to have surgery during the study period;

10. History of solid organ and bone marrow transplants;

11. Participated in any clinical trials within 3 months prior to screening.

12. Other conditions that, in the investigator's judgment, are unsuitable for study participation, such as factors that, in the investigator's judgment, pose a risk to the safety of the subject or interfere with the study evaluation, procedure, or completion.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Quadruple

Lead Sponsor

HJB (Hangzhou) Co., Ltd.INDUSTRY

Lh2116@126.com02583106666

Juanli2003@163.com025-83106666

• Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass

  NCT07806331

  Not yet recruitingInterventionalPhase 2Updated Sep 11, 2026
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection in Postmenopausal Women

  NCT05930704

  Unknown statusInterventionalPhase 1Updated Jul 17, 2023
• A Multiple Dose Study to Evaluate the Effect of SHR-1222 Injection in Postmenopausal Osteoporosis Patients

  NCT04435158

  CompletedInterventionalPhase 1Updated Jul 6, 2023
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women

  NCT01224717

  CompletedInterventionalPhase 1Updated May 13, 2011
• A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women

  NCT05225857

  CompletedInterventionalPhase 1Updated Feb 5, 2024
• Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis

  NCT05278338

  Unknown statusInterventionalPhase 2Updated Jul 18, 2022